The evolving role of toll-like receptors in diabetic vascular complications.
Laboratory of Atherosclerosis and Metabolic Research, Department of Pathology, University of California Davis Medical Center, Sacramento, CA; Veterans Affairs Medical Center, Mather, CA. Electronic address: ishwarlal.jialal@ucdmc.ucdavis.edu.
Ishwarlal
I
Jialal
Laboratory of Atherosclerosis and Metabolic Research, Department of Pathology, University of California Davis Medical Center, Sacramento, CA.
Roma
R
Pahwa
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D003925:Diabetic Angiopathies / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism*; D003928:Diabetic Nephropathies / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism*; D015507:Drugs, Investigational / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008955:Models, Cardiovascular; D051195:Toll-Like Receptor 2 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D051197:Toll-Like Receptor 4 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D015507:Drugs, Investigational; D007004:Hypoglycemic Agents; C495342:TLR2 protein, human; C495345:TLR4 protein, human; D051195:Toll-Like Receptor 2; D051197:Toll-Like Receptor 4